Show simple item record

dc.contributor.author Mouraviev, V
dc.contributor.author Johansen, TE
dc.contributor.author Polascik, TJ
dc.coverage.spatial United States
dc.date.accessioned 2011-04-15T16:46:23Z
dc.date.issued 2010-05
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/20443724
dc.identifier.citation J Endourol, 2010, 24 (5), pp. 827 - 834
dc.identifier.uri http://hdl.handle.net/10161/3235
dc.description.abstract The concept of focal therapy is rapidly evolving and gaining popularity from both physician and patient perspectives. We review the rationale, candidate selection, and results of the first clinical studies of focal cryoablation for selected patients with low volume and low- to low-moderate-risk features of prostate cancer as an alternative to whole-gland treatment. In spite of improved understanding of the tumor biology of early stage disease, we currently have limited tools to select appropriate patients with low- to low-moderate risk unifocal or unilateral prostate cancer who may be amenable to focal therapy. From a technical point, a number of ablative treatment options for focal therapy are available, with cryoablation having the most clinical experience. Recently, several reports have been published from single and multi-institutional studies that discuss focal therapy as a reasonable balance between cancer control and quality-of-life outcomes. Retrospective pathologic data from large prostatectomy series, however, do not clearly reveal valid and reproducible criteria to select appropriate candidates for focal cryoablation because of the complexity of tumorigenesis in early stage disease. At this time, a more feasible option remains hemiablation of the prostate with reasonable certainty about the absence of clinically significant cancer lesion(s) on the contralateral side of the prostate based on three-dimensional transperineal prostate biopsy mapping studies. Minimally invasive, parenchyma-preserving cryoablation can be considered as a potential feasible option in the treatment armamentarium of early stage, localized prostate cancer in appropriately selected candidates. There is a need to further test this technique in randomized, multicenter clinical trials.
dc.format.extent 827 - 834
dc.language ENG
dc.language.iso en_US en_US
dc.relation.ispartof J Endourol
dc.relation.isversionof 10.1089/end.2009.0546
dc.subject Cryosurgery
dc.subject Humans
dc.subject Male
dc.subject Patient Selection
dc.subject Prostatic Neoplasms
dc.subject Treatment Outcome
dc.title Contemporary results of focal therapy for prostate cancer using cryoablation.
dc.type Journal Article
dc.description.version Version of Record en_US
duke.date.pubdate 2010-5-0 en_US
duke.description.endpage 834 en_US
duke.description.issue 5 en_US
duke.description.startpage 827 en_US
duke.description.volume 24 en_US
dc.relation.journal Journal of Endourology en_US
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/20443724
pubs.issue 5
pubs.organisational-group /Duke
pubs.organisational-group /Duke/School of Medicine
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Surgery
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Surgery/Surgery, Urology
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers/Duke Cancer Institute
pubs.publication-status Published
pubs.volume 24
dc.identifier.eissn 1557-900X

Files in this item

This item appears in the following Collection(s)

Show simple item record